Beacon Accelerator is a Florida corporation holding an incubator for life sciences businesses at early-to-late research and development stages. The venture will be located in a 160,000 square feet facility in Jupiter currently being developed by an affiliated party, Beacon Pharmaceutical Jupiter, LLC. Beacon Accelerator is part of the public-private initiative with the Town of Jupiter, Florida, to develop further the life science R&D ecosystem in Jupiter, Florida. Beacon Capital has been working closely with the town of Jupiter for over a year and the local government is supportive of the Project.
Beacon-Accelerator has two goals:
To improve life sciences for all: We will empower smaller life sciences companies with the tools typically only available to larger biotech or pharma, allowing them to benefit fully from their intellectual property and entrepreneurial energy. We are amalgamating, streamlining and democratizing access to established tools and processes that are currently too disparately configured and capital intensive thus imposing hurdles to progress in life science discoveries. The secular trends driving growth in early-to-late stage life sciences businesses underpin our business model.
There have been four major driving factors over the last two decades:
The human condition: Globalization has resulted in increasing awareness of the range and connectedness of our diseases, for example:
Demography drives the need for more effective therapies with the growth and aging of the baby boomer generation as we tend to live longer. Huge populations are impacted by this, in the developed and the developing world;
Connectivity means that viral diseases, in particular, are able to spread swiftly, as we have seen of late. There is likely to be an increasing need for research and development of appropriate vaccines and therapies in the areas of the adaptive and innate immune system as well as other key indications which currently drive the therapeutic sector;
The breadth and sheer volume: There are approximately 10,000 known diseases, only 500 of which are currently addressable with treatments
Scientific breakthroughs: Increasing focus on, and successes in, biomolecular solutions for diagnostic and therapeutic problems, yielding disease-altering therapeutics, and a new era of biologic manufacturing and novel drug discovery.
Structural changes in the industry: Big Pharma’s patents on many well-established and lucrative drugs have expired or are about to expire, requiring them to look for the “next big thing”: contrast that with the more recent success of biotech, resulting in a secular and structural shift from chemical-based small molecules to humanized peptide-based biologics, biosimilars, and bio-betters and their complex formulations and manufacturing. Recent global events highlight the immediate and urgent need for USA-centric biotechnology operations, which can research, develop, manufacture, and ultimately, get new drugs and compounds rapidly and efficiently through the FDA approval process
Constant change is the norm: The life sciences industry is evolving rapidly, and under increasing pressure to produce advanced therapeutics and vaccines targeting: Oncology, Immunology, Cardiology, Aging, Central Nervous System (CNS)-related diseases such as Alzheimer, Parkinson, and ALS, and Infectious Diseases. We aim, through our APCs to be part of a solution that intends to deliver a diversified pipeline of preventative, regenerative, and disease-altering therapeutics.
Pathogens: As it is undeniably being demonstrated by the current SARS-CoV-2 (“COVID-19”) virus pandemic, there exists a clear and present danger for known and unknown pathogens, several of which evolve rapidly. Unfortunately, the current COVID-19 pandemic proves that the world has learned little since the 1918 Spanish Flu pandemic. Despite frequent wake-up calls the world remains largely unprepared.